This agent also has promising blood brain barrier permeability with a brain:plasma ratio of 0.9 in rats (Personal Communication, Peloton Therapeutics), thus allowing for preclinical evaluation of HIF2α inhibition in glioblastoma. This evidence concerns the gene EPAS1 and glioblastoma.